Table 1 Key characteristics of the participants age, growth, weight, pubertal development and glucocorticoid (GC) treatment
| Prednisolone | Deflazacort | GC previously | GC naïve | Total | |
|---|---|---|---|---|---|
| n = 19 | n = 25 | n = 6 | n = 12 | n = 62 | |
| Age | 9.6 (±3.0) | 11.6 (±2.9) | 16.6 (±1.4) | 8.9 (±5.8) | 11.0 (±4.2) |
| Age at diagnosis | 4.3 (±1.8) | 3.6 (±1.9) | 5.3 (±2.7) | 3.8 (±2.3) | 4.0 (±2.0) |
| Age at loss of ambulation | 10.5 (±1.8) n = 3 (15.8%) | 10.8 (±2.5) n = 6 (25.0%) | 11.6 (±1.9) n = 6 (85.7%) | 9.6 (±0.9) n = 5 (41.7%) | 10.7 (±1.9) n = 20 (32.3%) |
| GC initiated | 6.1 (±2.3) | 5.3 (±1.3) | 7.8 (±1.6) | N/A | 5.9 (±1.9) |
| GC duration | 3.8 (±3.2) | 6.3 (±3.3) | 4.6 (±3.0) | N/A | 5.2 (±3.4) |
| GC stopped | N/A | N/A | 11.9 (±3.1) | N/A | 11.8 (±3.1) |
| GC dose at time of investigationa | 0.49 (±0.13) mg/kg/d | 0.49 (±0.20) mg/kg/d | N/A | N/A | N/A |
| Height for age perc. (95% CI) | 13.0 (4.4, 21.7) | 5.2 (0.2, 10.2) | 28.0 (2.2, 53.7) | 32.2 (14.4, 49.9) | 15.5 (10.0, 21.1) |
| Weight for age perc. (95% CI) | 62.2 (46.3, 78.0) | 41.8 (27.6, 56.1) | 52.1 (8.4, 95.9) | 54.3 (34.7, 73.9) | 51.6 (42.8, 60.3) |
| Iso-BMI | 21.6 (4.7) | 22.4 (5.2) | 22.1 (8.6) | 18.3 (2.6) | 21.2 (5.0) |
| Tanner | 1–2 | 1–3 | 2–5 | 1–5 |